These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24939490)

  • 21. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotics.
    Dalal KS; Bridgeman MB
    Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
    [No Abstract]   [Full Text] [Related]  

  • 25. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin or oritavancin for skin infections.
    Cormican M
    N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
    [No Abstract]   [Full Text] [Related]  

  • 30. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
    Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
    Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three new agents added to the arsenal to fight MRSA.
    Strain J
    S D Med; 2014 Dec; 67(12):513-4. PubMed ID: 25571620
    [No Abstract]   [Full Text] [Related]  

  • 32. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
    Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
    Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
    Zervou FN; Zacharioudakis IM; Mylonakis E
    Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226
    [No Abstract]   [Full Text] [Related]  

  • 34. Dalbavancin or oritavancin for skin infections.
    Corey GR; Jiang H; Moeck G
    N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
    [No Abstract]   [Full Text] [Related]  

  • 35. Dalbavancin or oritavancin for skin infections.
    Baang J; Fisher S
    N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
    [No Abstract]   [Full Text] [Related]  

  • 36. Dalbavancin or oritavancin for skin infections.
    Núñez-Núñez M; Rodríguez-Baño J
    N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
    [No Abstract]   [Full Text] [Related]  

  • 37. Dalbavancin or oritavancin for skin infections.
    Boucher HW; Talbot GH; Dunne MW
    N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
    [No Abstract]   [Full Text] [Related]  

  • 38. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
    Roecker AM; Pope SD
    Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First vanguard anti-MRSA agent approved.
    Fox JL
    Nat Biotechnol; 2014 Jul; 32(7):603. PubMed ID: 25004211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.